Difference between revisions of "Hoffmann M, et al, Journal (2020), cited as Ref 39 in DOI: 10.1016/j.clim.2020.108427 (Q11282)"
Jump to navigation
Jump to search
(Created claim: Thirteenth Author string (P161): Pohlmann S, #quickstatements; #temporary_batch_1593104502035) |
(Created claim: title (P93): SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, #quickstatements; #temporary_batch_1593105300644) |
||
| Property / title | |||
| + | SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor (English) | ||
| Property / title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor (English) / rank | |||
| + | Normal rank | ||
Revision as of 17:16, 25 June 2020
Cited in: "COVID-19 pathophysiology: A review" Clin Immunol; 2020 Apr 20 108427.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Hoffmann M, et al, Journal (2020), cited as Ref 39 in DOI: 10.1016/j.clim.2020.108427
|
Cited in: "COVID-19 pathophysiology: A review" Clin Immunol; 2020 Apr 20 108427.
|
Statements
Journal
0 references
2020
0 references
Hoffmann M
0 references
Kleine-Weber H
0 references
Schroeder S
0 references
Kruger N
0 references
Herrler T
0 references
Erichsen S
0 references
Schiergens TS
0 references
Herrler G
0 references
Wu NH
0 references
Nitsche A
0 references
Muller MA
0 references
Drosten C
0 references
Pohlmann S
0 references
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor (English)
0 references
